Latest news with #SeanTucker
Yahoo
2 days ago
- Business
- Yahoo
Vaxart Announces Adjournment of Annual Meeting of Stockholders
SOUTH SAN FRANCISCO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) ('Vaxart' or the 'Company') announced today that its 2025 annual meeting of stockholders (the 'Annual Meeting') has been adjourned to Friday, June 13, 2025 at 8:30 a.m. Pacific Time with respect to all proposals described in Vaxart's definitive proxy statement filed with the U.S. Securities and Exchange Commission (the 'SEC') on April 10, 2025 (the 'Proxy Statement'). 'In recent days, we have engaged in constructive conversations with some of our larger stockholders to address their questions and concerns regarding the reverse stock split proposal,' said Steven Lo, Chief Executive Officer of Vaxart. 'I am pleased to report that following these discussions, many have indicated their intention to vote in favor of Proposal No. 2. This shift underscores the increasing understanding of the necessity of this proposal to ensure our continued Nasdaq listing as we focus on our exciting upcoming milestones.' The reconvened Annual Meeting will be held in a virtual-only format, which can be accessed by visiting and entering the 16‐digit control number included in your Notice of Internet Availability of Proxy Materials, on your proxy card or in the instructions that accompanied your proxy materials. During the adjournment, Vaxart continues to solicit votes from its stockholders with respect to all proposals set forth in the Proxy Statement. Proxies previously submitted with respect to the Annual Meeting will be voted on all applicable proposals at the adjourned Annual Meeting unless properly revoked in accordance with the procedures described in the Proxy Statement, and stockholders who have previously submitted a proxy or otherwise voted need not take any action. Both leading independent proxy advisory firms, Institutional Shareholder Services ('ISS') and Glass Lewis, recommend that stockholders support Proposal No. 2. A message from Dr. Sean Tucker, Founder and Chief Scientific Officer, and a fact sheet that addresses several misconceptions about the proposed reverse stock split can be found on Vaxart's investor relations website at Vaxart encourages all stockholders of record on March 26, 2025 who have not yet voted to do so by 11:59 p.m. Eastern Time on June 12, 2025. The Company also reminds those who have previously voted against Proposal No. 2 that they can change their vote in favor of the proposal. If you have any questions or need assistance with voting, please contact Vaxart's proxy solicitation firm: Campaign Management, LLCToll-Free: 1-855-264-1527Email: info@ About Vaxart Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart's development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart's first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists. Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the 'Securities Act') and Section 21E of the Securities Exchange Act of 1934, as amended (the 'Exchange Act'), which are subject to the 'safe harbor' created by those sections, concerning our business, operations, and financial performance and condition as well as the annual meeting of stockholders, our plans, objectives, and expectations for business operations, funding, and financial performance and condition. Any statements contained herein that are not of historical facts may be deemed to be forward-looking statements. You can identify these statements by words such as 'anticipate,' 'assume,' 'believe,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'should,' 'will,' 'would,' and other similar expressions that are predictions of or indicate future events and future trends. These forward-looking statements are based on current expectations, estimates, forecasts, and projections about our business and the industry in which we operate and management's beliefs and assumptions and are not guarantees of future performance or development and involve known and unknown risks, uncertainties, and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this press release may turn out to be inaccurate. Factors that could materially affect our business operations and financial performance and condition include, but are not limited to, those risks and uncertainties described under 'Item 1A - Risk Factors' in our Annual Report on Form 10-K for the year ended December 31, 2024 and any risk factors disclosed in any subsequent Quarterly Reports on Form 10-Q. You are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on the forward-looking statements. The forward-looking statements are based on information available to us as of the date of this press release. Unless required by law, we do not intend to publicly update or revise any forward-looking statements to reflect new information or future events or otherwise. You should, however, review the factors and risks we describe in the reports we will file from time to time with the SEC after the date of this press release. Participants in the SolicitationThe Company and its directors, executive officers, and certain employees and other persons may be deemed to be participants in the solicitation of proxies from the Company's stockholders in connection with the business to be conducted at the annual meeting of stockholders. Investors and security holders may obtain more detailed information regarding the names, affiliations, and interests of the Company's directors and executive officers in the definitive proxy statement filed in connection with the annual meeting of stockholders as well as the Company's other filings with the U.S. Securities and Exchange Commission (the 'SEC'), all of which may be obtained free of charge at the website maintained by the SEC at Contact Vaxart Media and Investor RelationsMatt SteinbergFINN PartnersIR@ 871-8481 This press release was published by a CLEAR® Verified in to access your portfolio
Globe and Mail
7 days ago
- Business
- Globe and Mail
Vaxart's Founder and Chief Scientific Officer Provides Video Update to Stockholders
Dr. Sean Tucker, Founder and CSO of Vaxart, Urges Stockholders to Vote FOR Reverse Stock Split Proposal by 11:59 p.m. Eastern Time on June 1, 2025 Company Corrects Record on Common Misconceptions Regarding the Reverse Stock Split Proposal SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the 'Company' OR 'Vaxart') today announces a video update for stockholders by Dr. Sean Tucker. The video is available on Vaxart's investor relations website at In the video, Dr. Tucker urges stockholders to vote FOR Proposal No. 2, which grants the Board of Directors authority to implement a reverse split that would enable Vaxart regain compliance with Nasdaq's minimum bid price rule. Additionally, to ensure stockholders have accurate information as they consider this important proposal, the Company addresses several misconceptions in the attached fact sheet: A PDF accompanying this announcement is available at Vaxart encourages all stockholders of record on March 26, 2025 who have not yet voted to do so by 11:59 p.m. Eastern Time on June 1, 2025. The Company also reminds those who have previously voted against Proposal No. 2 that they can change their vote in favor of the proposal. If you have any questions or need assistance with voting, please contact Vaxart's proxy solicitation firm: Campaign Management, LLC Toll-Free: 1-855-264-1527 Email: info@ About Vaxart Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart's development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart's first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists. Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the 'Securities Act') and Section 21E of the Securities Exchange Act of 1934, as amended (the 'Exchange Act'), which are subject to the 'safe harbor' created by those sections, concerning our business, operations, and financial performance and condition as well as our plans, objectives, and expectations for business operations, funding, financial performance and condition, and regaining compliance with the Nasdaq minimum bid price requirement. Any statements contained herein that are not of historical facts may be deemed to be forward-looking statements. You can identify these statements by words such as 'anticipate,' 'assume,' 'believe,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'should,' 'will,' 'would,' and other similar expressions that are predictions of or indicate future events and future trends. These forward-looking statements are based on current expectations, estimates, forecasts, and projections about our business and the industry in which we operate and management's beliefs and assumptions and are not guarantees of future performance or development and involve known and unknown risks, uncertainties, and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this press release may turn out to be inaccurate. Factors that could materially affect our business operations and financial performance and condition include, but are not limited to, those risks and uncertainties described under 'Item 1A - Risk Factors' in our Annual Report on Form 10-K for the year ended December 31, 2024 and any risk factors disclosed in any subsequent Quarterly Reports on Form 10-Q. You are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on the forward-looking statements. The forward-looking statements are based on information available to us as of the date of this press release. Unless required by law, we do not intend to publicly update or revise any forward-looking statements to reflect new information or future events or otherwise. You should, however, review the factors and risks we describe in the reports we will file from time to time with the SEC after the date of this press release. Participants in the Solicitation The Company and its directors, executive officers, and certain employees and other persons may be deemed to be participants in the solicitation of proxies from the Company's stockholders in connection with the business to be conducted at the annual meeting of stockholders. Investors and security holders may obtain more detailed information regarding the names, affiliations, and interests of the Company's directors and executive officers in the definitive proxy statement filed in connection with the annual meeting of stockholders as well as the Company's other filings with the U.S. Securities and Exchange Commission (the 'SEC'), all of which may be obtained free of charge at the website maintained by the SEC at This press release was published by a CLEAR® Verified individual.
Yahoo
17-05-2025
- Automotive
- Yahoo
Subaru stuns with bold new EV designed for extreme outdoor performance: 'Feels like a breath of fresh air'
Subaru's Solterra successor has a lot to offer. The Japanese car brand unveiled its newest electric vehicle, the Trailseeker, at the 2025 New York International Auto Show. It's a big moment for Subaru, as it is fairly new to the EV scene. The Trailseeker features over 8 inches of ground clearance and all-wheel drive, making it a decent choice for off-road adventures. With a 3,500-pound towing capacity and roof rails, the Trailseeker can haul boats, trailers, and more. The model is compatible with the North American Charging Standard, so drivers can charge at thousands of stalls across the United States. Refueling time is quick, too, going from 10% to 80% charge in just 30 minutes. The Trailseeker's price tag has yet to be revealed, but the "the average transaction price for electric cars was $59,205 in March," according to data from Kelley Blue Book. Since the vehicle's production is overseas, tariffs will likely raise the price. Despite the "chaos and the uncertainty over the future [of] the auto industry, the Trailseeker EV feels like a breath of fresh air," said Suvrat Kothari at InsideEVs. EV prices are closing in on their gas-powered counterparts, especially when combined with government incentives like tax credits and rebates. That's not to mention the money you would save on gas, which could be anywhere from hundreds to thousands of dollars a year, depending on usage. There are environmental benefits, too, since electric vehicles produce no planet-warming tailpipe emissions when out on the road. Even when factoring in production-related pollution, electric vehicles are still far better for the environment compared to gas guzzlers. Subaru's Solterra wasn't extremely successful, but the Trailseeker shows promise. If you were going to purchase an EV, which of these factors would be most important to you? Cost Battery range Power and speed The way it looks Click your choice to see results and speak your mind. "The Trailseeker enters the most competitive EV space," said Sean Tucker of Kelley Blue Book. "But it's an attractive package with the styling and spirit that Subaru loyalists expect, and helps solve some of the Solterra's limitations." Join our free newsletter for good news and useful tips, and don't miss this cool list of easy ways to help yourself while helping the planet.
Yahoo
21-03-2025
- Business
- Yahoo
Vaxart Inc (VXRT) Q4 2024 Earnings Call Highlights: Revenue Surge and Strategic Adjustments ...
Revenue for 2024: $28.7 million, up from $7.4 million in 2023. Cash Equivalents and Investments: $51.7 million at the end of 2024. Cash Runway: Anticipated into the fourth quarter of 2025. Expense Reduction: Implemented measures including workforce reduction following BARDA stop work order. Warning! GuruFocus has detected 6 Warning Signs with VXRT. Release Date: March 20, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Vaxart Inc (NASDAQ:VXRT) has developed a robust body of data across multiple clinical studies, demonstrating promising safety and immune response benefits of their oral vaccine platform. The company has initiated a Phase 1 trial for their second-generation oral Norovirus vaccine, which shows potential for improved potency over the first-generation constructs. Vaxart Inc (NASDAQ:VXRT) received a $460 million award to conduct a large-scale study comparing their COVID-19 vaccine candidate to an mRNA comparator, indicating significant external validation and support. The Norovirus vaccine program has shown promising efficacy in reducing infection rates and viral shedding, with a benign safety profile consistent with previous studies. The company is exploring strategic partnerships and non-dilutive funding options to extend their cash runway, demonstrating proactive financial management. A stop work order was issued for the BARDA-funded COVID-19 study, halting activities related to the planned 10,000 participant portion, creating uncertainty about the project's future. Vaxart Inc (NASDAQ:VXRT) had to implement expense reductions, including workforce reductions, due to the stop work order, indicating financial strain. There are no new updates on the 10,000 participant portion of the COVID-19 trial, leaving stakeholders in the dark about the project's progress. The company faces competition in the Norovirus vaccine market, with a competitor already in Phase 3 trials, potentially impacting market share. Vaxart Inc (NASDAQ:VXRT) ended 2024 with $51.7 million in cash equivalents and investments, which may not be sufficient to sustain operations without additional funding or partnerships. Q: Can you provide details on the new Phase 1 study for Norovirus, specifically whether the second-generation product is bivalent or monovalent, and the demographics of the trial participants? A: The Phase 1 study is enrolling participants aged 18 to 49. The second-generation product includes G11 and G24 constructs. Minor changes to the DNA backbone and antigen sequence have enhanced expression in intestinal epithelial cells, leading to greater immune responses in preclinical models. (James Cummings, Chief Medical Officer; Sean Tucker, Chief Scientific Officer) Q: How might the greater immune response seen in animal data for the second-generation Norovirus vaccine translate to efficacy in humans? A: The expectation is that even a small increase in immune response in humans could significantly improve protective efficacy due to the exponential amplification of the signal. This is based on mathematical modeling of necessary antibodies in the intestinal space and serum. (Sean Tucker, Chief Scientific Officer) Q: What immunogenicity measurements should be focused on for the Norovirus Phase 1 study, and how do they translate into protective efficacy? A: The study will measure serum Norovirus blocking antibody assay titers and fecal IgA, both of which correlated with protection in previous challenge studies. These are key indicators of efficacy. (Sean Tucker, Chief Scientific Officer) Q: Has the FDA seen the data for the COVID-19 sentinel cohort, and what was their response? A: Yes, the data was sent to the FDA simultaneously with the DSMB. The DSMB recommended proceeding without modifications, underscoring the robust safety profile of the vaccine candidate. The FDA has reviewed the data, and there is no hold on moving the program forward. (James Cummings, Chief Medical Officer) Q: How does the stop work order impact manufacturing for the COVID-19 trial, and what is the shelf life of the product? A: Vaxart maintains its own GMP manufacturing facilities in the U.S., allowing quick pivots in support of trials. The shelf life of the product is expected to last for two years, and the company is confident in adjusting to the stop work order as needed. (Ray Stapleton, Chief Technical Officer) For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
Yahoo
06-03-2025
- Sport
- Yahoo
NFL Rumors: Bucs ready to give Sean Tucker more work?
The Tampa Bay Buccaneers have one of the best roster builders in the NFL, Jason Licht. Whenever you are able to build a deep roster, players can get left out, and that will lead to them being cut or traded to make way for others buried in the depth chart that has shown promise. For the Bucs specifically, their running back depth chart has become of the best positions on the team. Not to mention, one of the best groups in the entire NFL. There have been rumblings that the team may move on from Rachaad White after the emergence of rookie Bucky Irving last year. White had over 1,000 yards from scrimmage last season as well, but that may not be enough for the Bucs. NBC Sports analyst Matthew Berry gathered his notes from everything he heard at the Scouting Combine last week and one of the rumors he heard included Rachaad White and Sean Tucker. "But perhaps the most interesting part of the Tampa Bay running back discussion was about Sean Tucker. 'He has the talent to be a No. 1 RB in this league,' said a team source. The issue is just that he's stuck behind Bucky Irving. Reading between the lines of the conversation, I came away thinking they love Irving, they love Tucker and aren't as enthusiastic about Rachaad White. I bet Tucker overtakes White for the RB 2 role sooner than later." The idea of going to Sean Tucker is interesting from the outside looking in. Against the Saints in Week 6, Tucker accumulated a whopping 192 total yards of offense. He earned FedEx Ground Player of the Week but never saw the same type of usage after. The team never gave him more than eight carries in a game after that, which confused everyone. If the team moves on from White, then Tucker could be in play for a major promotion within the dynamic Bucs offense. This article originally appeared on Bucs Wire: NFL Rumors: Bucs ready to give Sean Tucker more work?
